Atropine is used to treat certain types of poisoning (like nerve gas or pesticide exposure) and to dilate pupils during eye exams. It can also help reduce symptoms like excessive sweating, salivation, and muscle twitching caused by specific conditions.[2] Atropen is currently approved and in use across 29 indications[4].[1]
Atropen is one of 495 small molecule programs targeting Insulin resistance. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
2828 competitors in Breast Cancer
Atropen
Halaven
Tykerb
Tecentriq
Trodelvy
Adriamycin
Avastin
Nolvadex
Prolia
Gemzar
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Sep 19, 1990
ATROPINE SULFATE
NDA NDA020056
Jul 9, 2001
ATROPINE SULFATE
NDA NDA021146
Sep 17, 2004
ATROPEN
NDA NDA017106
Jul 18, 2014
ATROPINE SULFATE
NDA NDA206289
Dec 1, 2016
ISOPTO ATROPINE
NDA NDA208151
Jan 26, 2018
ATROPINE SULFATE
NDA NDA209260
Jul 9, 2018
ATROPINE (AUTOINJECTOR)
NDA NDA212319
Sep 29, 2020
ATROPINE SULFATE
NDA NDA214652
Mar 15, 2022
ATROPINE SULFATE
NDA NDA213581
Sources
Details